Nightstar Therapeutics to Present at the Deutsche Bank 43rd Annual Health Care Conference

By , in PR PR Health on .

LEXINGTON, Mass. and LONDON, April 30, 2018 — Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company will participate in the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8 at 4:10 p.m. ET in Boston, MA.
To access the live webcast, please visit ir.nightstartx.com. A replay of the webcast will be available on the Nightstar website for two weeks following the conference.About NightstarNightstar is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. Nightstar’s lead product candidate, NSR-REP1, is currently in Phase 3 development for the treatment of patients with choroideremia, a rare, degenerative, genetic retinal disorder that has no current treatments. Results from a Phase 1/2 trial of NSR-REP1 were published in The Lancet in 2014 and in The New England Journal of Medicine in 2016. Nightstar’s second product candidate, NSR-RPGR, is currently being evaluated in a Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease.For more information about Nightstar or its clinical trials, please visit www.nightstartx.com.Contacts:
Senthil Sundaram, Chief Financial Officer
Brian Luque, Sr. Manager, Investor Relations
[email protected]

The following two tabs change content below.
Jasmine Petters

Jasmine Petters

Jasmine hails from the city of Nizams, Hyderabad, and is currently pursuing her M.D. from there only. She is an internet wizard and has keen passion in All Things tech. She is a regular Comment contributor for The Daily Telescope and writes a Web column, in which she covers war, sports, and everything in between.
%d bloggers like this: